Oslo Cancer Cluster member Photocure ASA is a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology. They reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 (Q3 2015: NOK 27.0) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 8.0 million.
Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. They develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, HPV and precancerous lesions of the cervix and acne.
Photocure currently have one product on the market: Hexvix®/Cysview® (The brand name is Cysview in the US and Hexvix in the rest of the world).
The Photocure Technology® is uniquely selective, targeting affected areas without impact to non-affected areas. This allows for non-invasive procedures that improve quality of life.